BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) Director Jennifer Cook sold 148,589 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the completion of the sale, the director directly owned 8,383 shares of the company’s stock, valued at $742,230.82. The trade was a 94.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
BridgeBio Pharma Stock Down 1.7%
Shares of BBIO stock opened at $82.66 on Thursday. The firm has a market cap of $16.19 billion, a price-to-earnings ratio of -22.10 and a beta of 0.95. BridgeBio Pharma, Inc. has a 52-week low of $42.09 and a 52-week high of $93.42. The company’s 50 day moving average is $70.60 and its 200 day moving average is $72.22.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The business had revenue of $194.51 million during the quarter, compared to analyst estimates of $178.07 million. The company’s quarterly revenue was up 66.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.88) earnings per share. Analysts anticipate that BridgeBio Pharma, Inc. will post -2.29 EPS for the current fiscal year.
BridgeBio Pharma News Summary
- Positive Sentiment: HC Wainwright maintained a Buy rating and $120 price target on BridgeBio Pharma, while raising several longer-term earnings estimates, including FY2027 EPS to $2.19. This supports the view that analysts still see substantial upside potential. BridgeBio Pharma analyst report
- Positive Sentiment: HC Wainwright also increased its Q4 2026, Q2 2027, Q3 2027, and Q4 2027 EPS forecasts, suggesting improving expectations for BridgeBio’s profitability over time. BridgeBio Pharma analyst report
- Neutral Sentiment: The analyst slightly lowered near-term estimates for Q3 2026 and Q1 2027 EPS and trimmed FY2026 EPS, reflecting some caution on the company’s shorter-term earnings trajectory. BridgeBio Pharma analyst report
- Negative Sentiment: Director Andrea Ellis sold 17,167 shares worth about $1.44 million, a disclosure that can weigh on investor sentiment even though the trade was made under a pre-arranged 10b5-1 plan. Insider selling article
Hedge Funds Weigh In On BridgeBio Pharma
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Harvest Fund Management Co. Ltd purchased a new position in shares of BridgeBio Pharma during the 3rd quarter valued at about $34,000. Jones Financial Companies Lllp acquired a new stake in BridgeBio Pharma in the first quarter valued at approximately $35,000. Farther Finance Advisors LLC increased its position in shares of BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after buying an additional 245 shares in the last quarter. Global Retirement Partners LLC raised its stake in shares of BridgeBio Pharma by 271.5% during the 4th quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock worth $39,000 after buying an additional 372 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of BridgeBio Pharma during the 4th quarter worth about $41,000. Institutional investors and hedge funds own 99.85% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on BBIO. Morgan Stanley lifted their price objective on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a research report on Thursday, May 28th. Citigroup began coverage on BridgeBio Pharma in a report on Tuesday, May 19th. They set a “neutral” rating and a $82.00 price objective for the company. HC Wainwright boosted their target price on BridgeBio Pharma from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday. Canaccord Genuity Group initiated coverage on BridgeBio Pharma in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 price target for the company. Finally, Raymond James Financial lowered BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. Twenty research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $94.63.
View Our Latest Report on BBIO
About BridgeBio Pharma
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Featured Articles
- Five stocks we like better than BridgeBio Pharma
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
